TIGIT Drug Discovery Landscape & Assay Solutions

Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Immuno-Oncology Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for TIGIT drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen TIGIT ECD-Fc Fusion Protein
High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 expressed for native glycosylation.
View TIGIT Products
Gene Delivery TIGIT Lentivirus Particles
Full-length ORF for stable cell line generation. High titer, P2 packaging system.
View TIGIT Products
Benchmark Ab Anti-TIGIT (Tiragolumab Biosimilar)
Recombinant positive control, sequence verified, endotoxin controlled.
View TIGIT Products
Validator TIGIT siRNA Set
For knockdown verification and assay specificity controls. Sequence-verified targets.
View TIGIT Products
Primary Ligand PVR (CD155) Recombinant Protein
Primary binding partner. ECD-Fc format available for SPR/BLI.
View CD155 Products
Related Target A PD-1 (PDCD1)
Critical synergistic immune checkpoint for combination therapies.
View PDCD1 Products
Related Target B PVRIG (CD112R) Protein
Parallel immune checkpoint for combination strategy evaluation.
View PVRIG Products

Critical Assay Challenges & TarMart Advantages

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Cross-species bridging (Human/Cyno/Mouse) Human/Mouse/Cynomolgus TIGIT ortholog proteins available with >95% purity; sequence verified for epitope conservation analysis.
Ligand blocking / competition (vs. CD226, CD96, PVRIG) High-purity PVR/CD155, CD112, CD226, and PVRIG proteins for competitive binding SPR/BLI assays.
Fc engineering validation TIGIT ECD-Fc with wild-type and effector-null Fc backbones available (LALA/aglycosylated options).
Internalization assessment (for ADC) TIGIT Lentivirus for stable overexpression in target cell lines; compatible with pH-dependent tracer internalization assays.
Specificity controls & false positive reduction Validated siRNA included for target-specificity verification; clinical benchmark antibodies (Tiragolumab biosimilar) provided as positive controls.

Live TIGIT R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for TIGIT therapeutics is intensifying, with major players shifting focus from monotherapy to strategic combinations. Following Phase 3 setbacks with first-generation antibodies (e.g., Roche's Tiragolumab in SKYSCRAPER trials), the field is pivoting toward Fc-engineered silenced mAbs and bispecific formats targeting TIGIT/PD-1 axes. As biomarker-driven strategies (CD155-high expression) emerge, the next wave of R&D targets optimal Fc-effector function, selective epitope engagement, and reduced peripheral toxicity through affinity tuning. Overcoming resistance in non-small cell lung cancer (NSCLC) and other solid tumors remains a key priority.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Fc-silenced mAb (Monoclonal Antibody) Roche, GSK, Arcus/Gilead, Merck NSCLC, Esophageal Cancer, Solid Tumors FcγR binding assay (need WT vs Null Fc controls); high-purity ECD-Fc for structural studies. View TIGIT Products
Anti-TIGIT/PD-1 Bispecific AstraZeneca, Akeso, BioNTech, Compugen Advanced Solid Tumors Heterodimer validation (need TIGIT + PD-1 co-binding); cross-reactive reagents for dual-construct assays. View TIGIT Products
ADC Emergent Biotech Metastatic Solid Tumors Internalization Assay (need Lentivirus-stable overexpression lines); pH-sensitive tracer assays. View TIGIT Products
Combination Therapy BeiGene, Bristol Myers Squibb, AstraZeneca Immunotherapy Refractory, Relapsed/Refractory Cancers Combination index assays with CD155/PVRIG pathways; receptor competition assays need PVR/CD155 antigens. View CD155 Products